Spruce Biosciences Reports Improved Financial Performance and Strategic CostCutting Measures for FY23
Spruce Biosciences announced an EPS of $(1.24) for FY23, marking an improvement from $(1.96) compared to the previous year. Collaboration ...
Tag: SPRB
Spruce Biosciences Reaches Enrollment Milestone in CAHmelia204 Clinical Trial
Spruce Biosciences has reached a major milestone in its CAHmelia-204 clinical trial, surpassing its target enrollment of 90 patients by ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
